A variety of other kinase inhibitors are used or in trials for hematologic cancers (e.g. PI3K inhibitors like idelalisib, BCL2 inhibitor venetoclax, MEK inhibitors in trials for certain leukemias). Here, BCL2 is linked to hematopoietic and lymphoid cell neoplasm.